

**PRESS
RELEASE****STALLERGENES INAUGURATES
THE BIGGEST PHARMACEUTICAL ALLERGEN
PRODUCTION UNIT IN THE WORLD**

Antony, France (11 September 2008) Stallergenes S.A. officially inaugurates its new pharmaceutical production unit, located in Paris area.

Designed to comply with the most stringent EMEA (European Medicines Agency) and FDA (US Food and Drug Administration) standards, this unit will produce desensitisation treatments for all markets, primarily in Europe and North America. This investment worth more than 20 million euros will incorporate the production of the active substance for the Oralair[®] Grasses tablet and increase the production capacity for Staloral[®], to meet the needs of an expanding international marketplace.

“For Stallergenes, this investment marks a major step forward. This new production unit will help the company break into the tough U.S market and increase its production capacity tenfold,” states Albert Saporta, Chairman and CEO of Stallergenes.

ABOUT ORALAIR[®] GRASSES

Oralair[®] Grasses is a fast-dissolving sublingual desensitisation tablet indicated in allergic rhino-conjunctivitis caused by grass pollen for patients with moderate to severe symptoms unsatisfied with or inadequately controlled by symptomatic treatments. Oralair[®] Grasses contains a mix of five standardised grass allergens, mimicking patients' natural exposure: perennial rye grass (*Lolium perenne*), meadow grass (*Poa pratensis*), timothy grass (*Phleum pratense*), cocksfoot (*Dactylis glomerata*) and sweet vernal grass (*Anthoxanthum odoratum*). In June 2008, Oralair[®] Grasses was granted a marketing authorisation in adults in Germany and a paediatric extension of its indications is expected by the end of the year. Stallergenes then plans to launch a mutual recognition procedure in the near future, with a view to marketing Oralair[®] Grasses in other European countries in both indications.

ABOUT STALORAL[®]

Staloral[®] is an NPP (named patient product) sublingual solution (drops to be placed under the tongue) of allergen extracts. Staloral[®] is indicated in allergic

rhino-conjunctivitis caused by pollen, dust mites, mould and dander (animal hair). Staloral® is available in the majority of European countries.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatments, Stallergenes devotes 20% in raw data of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed on Euronext Paris (Compartment B) and is part of the sample composing the SBF 120 index.

ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP



To find out more, visit the website: <http://www.stallergenes.com>

Contacts

Albert Saporta – President and CEO
Tel.: +33 1 55 59 20 04

Christian Thiry – Financial V.P
Tel.: +33 1 55 59 20 95 – e-mail: investorrelations@stallergenes.fr

Stallergenes press relations

Lise Lemonnier – Communication Manager
Tel.: + 33 1 55 59 20 96 – e-mail: llemonnier@stallergenes.fr

Stallergenes investor and analyst relations

Lucile de Fraguier – Pavie Finance
Tel.: + 33 1 42 15 04 39 – e-mail: contact@pavie-finance.com